Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Emerging technologies such as organoids, three-dimensional (3D) printing technology, AI-driven drug discovery, single-cell transcriptomics, and CRISPR/Cas9 gene editing are significantly advancing the ability to target both hypoxia and CSCs, two key factors driving tumor progression and therapy resistance
[1] Richie JP, Muscat JE, Ellison I, et al
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Yin S, Wang Y, Yang X
When you click Copy Link, the URL includes parameters that restore those exact values when opened
PMID 3138230
US$ 28.67
US$ 27.62
US$ 28.79
US$ 29.57
US$ 29.66
US$ 21.10
US$ 24.32
